( Nasdaq : HTWR ; ASX : HIN ) , a leading innovator and provider of less invasive , miniaturized circulatory support technologies revolutionizing the treatment of advanced heart failure , today announced a significant increase in revenues to $ 7.5 million for the third quarter ended September 30 , 2009 .